Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (ACOG) Q4 2024
Dallas, Texas–(Newsfile Corp. – April 1, 2025) – Alpha Cognition Inc. (NASDAQ: ACOG): Stonegate Capital Partners updates their coverage on Alpha Cognition Inc. (NASDAQ: ACOG). Alpha Cognition had a strong 2024 after raising $52.8M and uplisting to NASDAQ, significantly enhancing its capital base and market visibility. It completed commercial manufacturing for its lead product ZUNVEYL (benzgalantamine), secured a new U.S. patent extending exclusivity through 2044, and concluded phase one of a Department of Defense-funded study demonstrating the potential to treat head trauma from blasts.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- Successfully launched in U.S. LTC market; raised $52.8M, uplisted to Nasdaq (ACOG), and secured patent protection through 2044.
- Signed $44M licensing deal for Asia; building international partnerships to diversify revenue and reduce risk.
- Strong start in $2B LTC market with experienced sales team; positive initial physician feedback driving awareness and adoption.
Click image above to view full announcement.
About Stonegate
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Our affiliate, Stonegate Capital Markets (member FINRA) provides a full spectrum of investment banking services for public and private companies.
Contacts:
Stonegate Capital Partners
(214) 987-4121
info@stonegateinc.com
Source: Stonegate, Inc.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247008
View more news from Reportable, Inc.
You are receiving this email because you have previously indicated your interest in receiving news for Reportable, Inc.
If you no longer want to receive messages from us, you can click here to unsubscribe.
Anti-Spam Policy | Privacy Policy